Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.01.10

Sai Schrödinger Research Laboratories

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India

Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Being built inside Sai Life Sciences’ R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry, in vitro biology, and process chemistry. It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed. The relationship will support advancement of programs that leverage Schrödinger’s validated computational platform.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “We’re truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories. In many ways, this is a testimony to the advances we have made in the scale, scope and depth of our integrated drug discovery capabilities. We are very excited about working with the Schrödinger team and, guided by our brand promise, will strive to make it better together.” Scheduled to open in April 2023, SSRL will commence with about 75 staff members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry, Analytical Chemistry, and other support staff. Recruitment has commenced for SSRL, and the open positions can be viewed here.

The Discovery business of Sai Life Sciences has been witnessing a transformative phase of growth in recent years, as is evidenced in its expanding client mix and diversity of programs. Powered by investments in talent, technology and capacity across Boston and Hyderabad, the company’s global delivery model is delivering unique value to its customers through an optimal blend of talent, speed, and cost efficiency. This journey typically starts with its exploratory biology facility in Boston, where the company works hand-in-hand with clients in real-time on early discovery biology programs that are difficult to outsource. These programs then transition to the company’s Hyderabad R&D campus, where it has consolidated its chemistry, biology and ADME-PK services in one integrated campus, allowing Sai scientists to work as teams and deliver quality data to its customers.

Share article

More News

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more